<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088360</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-045B</org_study_id>
    <nct_id>NCT01088360</nct_id>
  </id_info>
  <brief_title>Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)</brief_title>
  <official_title>An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Data Bank for Rheumatic Diseases (NDB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence rates of targeted infections,
      malignancies and mortality among patients with rheumatoid arthritis who are treated with
      abatacept and those who are treated with other anti-rheumatic medications.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2005</start_date>
  <completion_date type="Anticipated">June 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Key safety outcomes (targeted infections, malignancies, mortality)</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported infusion reactions</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple sclerosis, lupus, and psoriasis</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in pregnant women who receive abatacept</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in subjects on abatacept who receive concomitant biologics</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis initiating abatacept</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pts with RA initiating other biologic disease-modifying drugs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being treated for rheumatoid arthritis in the US
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Diagnosis of rheumatoid arthritis

          -  &gt; 18 years at index treatment initiation or switch

          -  Starting treatment with abatacept or new disease-modifying anti-rheumatic drug
             (including switching or adding) or biologic disease modifying drug.

          -  Read/write English

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

